<DOC>
	<DOCNO>NCT01253291</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability 48 week subcutaneous dose LY2127399 patient participate prior LY2127399 clinical study . At end 48 week treatment period , patient participate 24 week follow period . Additional follow week 72 may continue ass B cell recovery .</brief_summary>
	<brief_title>A Study Japanese Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Have give write informed consent Women must pregnant , breastfeed risk become pregnant study participation Must complete treatment 12 week follow period prior LY2127399 study Exclusion criterion Have safety event study LY2127399 patient participate previous Have receive , previous study , drug prohibit study protocol include unapproved drug , live vaccine , biologic nonbiologic DMARD except MTX , hydroxychloroquine , sulfasalazine bucillamine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>